You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF
Editorial commentary
MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis
  1. Akiyuki Uzawa,
  2. Masahiro Mori,
  3. Satoshi Kuwabara
  1. Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
  1. Correspondence to Dr Akiyuki Uzawa, Department of Neurology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; auzawa{at}chiba-u.jp

https://doi.org/10.1136/jnnp-2018-318231

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Is cerebrospinal fluid cytokine profile different in myelin oligodendrocyte glycoprotein-IgG-positive disorders, multiple sclerosis and anti-aquaporin 4 antibody-positive neuromyelitis optica?

    Multiple sclerosis (MS) and neuromyelitis optica (NMO) are autoimmune inflammatory disorders of the central nervous system (CNS). The discovery of the disease-specific anti-aquaporin 4 (AQP4) autoantibody was a breakthrough in the pathogenesis of NMO.1 MS and NMO are distinct diseases with different immunological backgrounds and thereby cerebrospinal fluid (CSF) cytokine profiles.2 Briefly, Th17 and Th2-related cytokines are upregulated in NMO but not in MS. Among elevated CSF cytokines, interleukin (IL)-6 was the most remarkable, and its level was closely related to the levels of astrocytic damage marker (CSF glia fibrillar acidic protein (GFAP)) and recovery from attacks,2 3 suggesting that CSF IL-6 could contribute to the NMO …

    View Full Text

    Footnotes

    • Contributors AU drafted the manuscript. MM and SK supervised the manuscript drafting.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles